SAN DIEGO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, announced that it will host its 2023 Investor R&D Day on Thursday, September 28, starting at 10 a.m. ET in New York City.
The format will feature presentations by Trey Martin, Chief Executive Officer, and other members of Maravai’s senior leadership team and conclude with a Q&A session.
You can access the live webcast of the presentation via the Investors section of our website, www.maravai.com. A replay of the webcast will be available following the presentation.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologic safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
| Last Trade: | US$3.75 |
| Daily Change: | 0.33 9.65 |
| Daily Volume: | 3,270,252 |
| Market Cap: | US$543.830M |
November 06, 2025 June 09, 2025 June 03, 2025 | |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
